NCT06742957View on ClinicalTrials.gov

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

560

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

November 28, 2025

Conditions
Plaque Type Psorisis
Interventions
DRUG

Tapinarof Cream 1%

Cream

DRUG

VTAMA®

Cream

DRUG

Placebo

Cream

Trial Locations (26)

11797

12127, Woodbury

15241

Site 12125, Upper Saint Clair

33027

Site 12114, Miramar

33144

Site 12104, Miami

33146

Site 12116, Miami

33175

Site 12113, Miami

33308

Site 12115, Fort Lauderdale

40241

Site 12105, Louisville

46410

Site 12123, Merrillville

47129

Site 12106, Clarksville

60008

Site 12121, Rolling Meadows

60614

Site 12108, Chicago

72022

Site 12101, Bryant

77070

Site 12117, Houston

77845

Site 12103, College Station

79925

Site 12118, El Paso

85260

Site 12107, Scottsdale

89121

Site 12109, Las Vegas

91325

Site 12120, Northridge

91767

Site 12111, Pomona

92647

Site 12119, Huntington Beach

94538

Site 12102, Fremont

94568

Site 12110, Dublin

Site 12112, Dublin

97210

Site 12126, Portland

06831

Site 12122, Greenwich

All Listed Sponsors
collaborator

Teva Pharmaceuticals, Inc.

INDUSTRY

lead

Teva Pharmaceuticals USA

INDUSTRY

NCT06742957 - Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | Biotech Hunter | Biotech Hunter